UK industry and National Health Service bodies say that the “political declaration” on the future UK-EU relationship fails to address key public health issues such as regulatory cooperation, collaboration in science and innovation, and tackling counterfeit medicines.
As prime minister Theresa May prepares to head to Brussels to discuss the future relationship between the UK and the EU after Brexit, a coalition of UK healthcare and life sciences organizations has called on both sides to ensure that public health matters are placed at the center of the negotiations.
The bare bones of the future relationship are currently sketched out in a short “political declaration” attached to the draft...
<p>Executive Summary</p> <p>A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.</p>
As the reform of the EU pharmaceutical legislation progresses through the legislative process, the Pinks Sheet offers an infographic highlighting some of the key changes being proposed that will reshape the way drug companies run their business.
<p>Executive Summary<p> <p>The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add six new products, incl/ding Ixchiq, Valneva's chikungunya virus vaccine</p>
A new research ethics review system for multi-site clinical trials in Canada is expected to help improve study start-up times, avoid unnecessary duplication and boost the country’s competitiveness on a global stage.
With the deadline for comments on the US FDA’s draft guidance less than a month away, the Pink Sheet offers an infographic outlining what the agency is expecting in diversity action plans and when that might be implemented.
